Aprea reports anti-proliferative results and promising early-stage clinical data for next-generation wee1 inhibitor, apr-1051, in hpv+ head and neck squamous cell carcinoma (hnscc) in collaboration with md anderson cancer center

Preclinical data demonstrate potent single-agent and combination effects in head and neck squamous cell carcinoma (hnscc) models, including synergy with anti–pd-1 therapy
APR Ratings Summary
APR Quant Ranking